Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Down 25.2% in December

Bone Biologics Corp. (NASDAQ:BBLG) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 40,434 shares, a drop of 25.2% from the December 15th total of 54,072 shares. Approximately 2.4% of the company’s shares are short sold. Based on an average daily volume of 1,479,210 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 1,479,210 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.4% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Bone Biologics from a “sell” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reissued a “sell (e)” rating on shares of Bone Biologics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bone Biologics has a consensus rating of “Sell”.

Bone Biologics Stock Up 6.6%

Shares of BBLG stock opened at $1.78 on Friday. Bone Biologics has a 12-month low of $1.30 and a 12-month high of $7.74. The firm has a fifty day moving average of $1.68 and a 200-day moving average of $2.21. The firm has a market capitalization of $3.20 million, a price-to-earnings ratio of -0.49 and a beta of 0.74.

Bone Biologics (NASDAQ:BBLG) last posted its earnings results on Friday, November 14th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.86. Research analysts expect that Bone Biologics will post -5 earnings per share for the current year.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.